TickerTalks
Browse all tickers →
TickerTalks›$RLAY
RLRLAY

Relay Therapeutics, Inc.

$RLAY·$3.5B·Biotechnology·Healthcare
$19.86-0.4%YTD+134.0%1Y+485.8%
Mentions · last 7 days
2026-08-08: 6 posts2026-08-09: 5 posts2026-08-10: 14 posts2026-08-11: 9 posts2026-08-12: 3 posts2026-08-13: 8 posts2026-08-14: 13 posts58+6%
Price updated 15h ago·X counts updated 13h ago
RLRLAY
$RLAYRelay Therapeutics, Inc.
$19.86-0.35%58 posts+6%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $RLAY, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventAcceleratingAI verdict · as of 2026-08-13

The move is getting stronger, with heavier trading behind it.

Precision-medicine biotech up 499% t12m — Perceptive +45% to 14.1M shares, $212M raise, zovegalisib Phase 3.

Relay Therapeutics is a Cambridge-based precision-medicine biotech (allosteric drug discovery using D.E. Shaw Research computational modeling) — flagship RLY-4008 (FGFR2), RLY-2608 (PI3Ka mutant), RLY-1971/GDC-1971 (SHP2, Genentech partnered). The stock is up 499% over 12 months and 134% YTD at 95% of the 52-week range as the multi-catalyst clinical thesis lands.

  • The Q2 print is a specific miss: EPS -$0.41 vs -$0.39 estimate (-4.8% miss on the small base), revenue $350K (below $960K estimate), and the last four EPS surprises are -4.8%, -17%, +16%, -10% (mixed on the tiny revenue base). Analysts model FY26 revenue $11.8M rising to $460M by FY30 (a specific hockey-stick).
  • The strategic-catalyst layer is genuinely fresh: Perceptive Advisors increased holdings 45% to 14.1M shares (a specific institutional accumulation signal), Citizens PT raised to $26, Guggenheim reiterated Buy at $26 — both citing zovegalisib's Phase 3 progress in 2L PIK3CAm HR+/HER2- breast cancer with best-in-class tolerability, promising vascular-malformation profile, and $911M cash into 2029 runway. Fresh $212M raise (16M shares at ~$13.30) funds this.
  • The counterweights are severe: 222x P/S is extreme even for a clinical-stage biotech, -9x TTM P/E, operating margin -28%, FCF yield -9%, ROIC -44%, small officer S-Sales on July 28 (Rahmer, Bergstrom, Catinazzo) are structural signals, and the Q2 revenue $350K vs $960K estimate shows Genentech-milestone timing volatility — plus 95% of 52w range means enthusiasm is largely priced.

The November 5 Q3 print is the next gate — a specific zovegalisib Phase 3 interim readout or full-data disclosure, continued RLY-4008 (FGFR2) commercial-timeline commentary, and updated runway guidance is what extends the accelerating tape above $28. A specific Phase 3 zovegalisib data miss, a fresh dilutive raise on top of the current $212M, or a Genentech-partnership commercial-terms disappointment is what would take a name at 95% of 52w range back below $14.

Agrees with X sentimentThe bullish 'Relay Therapeutics up ~5x in a year to nearly $20 with $4B+ market cap, Perceptive Advisors increased holdings 45% to 14.1M shares, Citizens PT raised to $26 and Guggenheim reiterated Buy at $26 both citing zovegalisib's Phase 3 progress in 2L PIK3CAm HR+/HER2- breast cancer, best-in-class tolerability, promising vascular-malformation profile, $911M cash into 2029, uniformly constructive tone' framing on X aligns with the setup.

What to watch: November 5 Q3 print — a specific zovegalisib Phase 3 interim readout, continued RLY-4008 commercial-timeline commentary, and updated runway guidance extends the accelerating tape above $28; a Phase 3 zovegalisib data miss, a fresh dilutive raise, or a Genentech-partnership commercial-terms disappointment takes it back below $14.

On the calendar: 2026-11-05 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment7 posts analyzed · as of 2026-08-14

Relay Therapeutics is strongly bullish. Citizens PT raised to $26 from $21 (Market Outperform) and Guggenheim PT $26 (Buy) on zovega Ph3 execution, YE Ph3 enrollment update expected, pooled ~40% of Ph3-size data giving confidence. Perceptive Advisors increased holding 44.66% to 6.4% ownership. YTD +143.47%, from $3 to $20.

Read the AI verdict + X sentiment for $RLAY

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Develops kinase inhibitor cancer drugs using protein motion simulation to design precision oncology therapies.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $RLAY.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $RLAY

Partial — Develops kinase inhibitor cancer drugs using protein motion simulation to design precision oncology therapies; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+44.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-8.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-44.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-27.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-9.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
221.6Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-43.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
89.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 6, 2026$-0.41$-0.39-4.8%
Q1 2026May 5, 2026$-0.41$-0.35-17.1%
Q4 2025Feb 26, 2026$-0.32$-0.38+15.8%
Q3 2025Nov 6, 2025$-0.43$-0.39-10.3%
Next earningsThu, Nov 5·consensus EPS $-0.39

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.0M-60.9%83.2%-2620%$-0.41$-51.1M
Q4 FY25$7.0M—91.4%-866%$-0.32$-44.9M
Q3 FY25$0———$-0.43$-62.1M
Q2 FY25$677K—100%-11351%$-0.41$-55.3M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$11.8M$7.0M – $18.7M-$1.55-$1.76 – -$1.339
FY27$16.0M$8.6M – $37.6M-$1.60-$1.66 – -$1.497
FY28$35.8M$19.2M – $84.0M-$1.51-$1.71 – -$1.2010
FY29$183.5M$98.7M – $431.2M-$1.01-$2.77 – -$0.405
FY30$460.4M$247.6M – $1.1B-$0.15-$0.42 – -$0.065

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.95%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+9.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+65.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 171.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.705-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 28Peter RahmerSee remarks748 sh$14KSellJul 28Donald A BergstromPresident2.2K sh$42KSellJul 28Thomas CatinazzoCFO1.5K sh$27KSellJul 7Sanjiv PatelCEO48.2K sh$944KSellJul 6Donald A BergstromPresident8.7K sh$162KSellJul 6Thomas CatinazzoCFO17.7K sh$331KSellJun 30Peter RahmerSee remarks50.0K sh$955KSellJun 22Thomas CatinazzoCFO69.3K sh$1.2MSellJun 22Donald A BergstromPresident93.5K sh$1.6MSellMay 14Thomas CatinazzoCFO17.7K sh$228K
1–10 of 16
+ 12 other (9 awards · 3 exempts) in window

See when $RLAY insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Aug 6424B5
AI summary

RLAY (RLAY) filed a prospectus supplement (Form 424B5) on 2026-08-06 for an immediate offering of 16,006,569 shares $0.001 per share, raising approximately $212,978,049 . Use of proceeds: general corporate purposes. This is dilutive capital activity happening now, distinct from a shelf registration — new shares will be issued. Investors should assess pricing relative to market and stated use of proceeds to evaluate dilution impact.

8-KMaterial agreementAug 68-K — Item 1.01: Material agreement · Item 2.02: Earnings release
AI summary

RELAY THERAPEUTICS, INC. (RLAY) reported earnings and disclosed a material agreement on 2026-08-06, reporting financial results details in attached press release. The press release notes: mission under the Securities Act of 1933, as amended (the “S. Additional items: Item 1.01. Quarterly earnings are a material disclosure; investors should review the full press release for segment details and management commentary.

8-KCharter amendmentJun 98-K — Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

Relay Therapeutics (RLAY) held its 2026 Annual Meeting on June 9, 2026, electing Class III directors Douglas Ingram (120.9M for) and Claire Mazumdar (122.9M for) to three-year terms through 2029. Separately, stockholders approved — and Relay immediately filed — a Certificate of Amendment increasing authorized common shares from 300 million to 450 million. The 50% authorized share expansion (approved by a majority of votes cast) was the most material action at the meeting, giving Relay significant additional capacity for future equity raises or acquisitions.

8-KMaterial agreementMay 218-K — Item 1.01: Material agreement
AI summary

Relay Therapeutics, Inc. (RLAY) filed an 8-K on May 20, 2026 disclosing a material definitive agreement (Item 1.01). Relay is a Cambridge, Massachusetts-based clinical-stage precision medicine company focused on protein motion science, listed on Nasdaq. Filed concurrently with Relay's $275M equity offering (424B5), this material agreement may relate to a licensing, collaboration, or acquisition that the equity raise is intended to support; the specific terms and counterparty are not visible in the excerpt.

424B5Prospectus supplement (offering)May 21424B5
AI summary

Relay Therapeutics, Inc. (RLAY) priced a public offering of 22,916,667 shares of common stock at $12.00 per share for gross proceeds of approximately $275 million, per a 424B5 filed May 21, 2026; the underwriting discount is $0.72/share ($16.5M total), yielding net proceeds of ~$258.5M before expenses, with a 30-day overallotment option for 3,437,500 additional shares. The offering price represents a modest discount to the last sale price of $12.20. This is a large dilutive primary equity raise for Relay Therapeutics, likely funding its precision oncology and protein motion drug discovery programs.

424B5Prospectus supplement (offering)May 19424B5
AI summary

Relay Therapeutics, Inc. (RLAY) filed a preliminary prospectus supplement for an underwritten public offering of $175 million of common stock, with a 30-day overallotment option for an additional $26.25 million, led by Jefferies, TD Cowen, Goldman Sachs, and Guggenheim Securities. The last reported sale price on May 15, 2026 was $12.20 per share; final per-share price and share count are not set in this preliminary supplement. This is a dilutive equity raise for a clinical-stage biotech, likely to fund the ReInspire Phase 2 trial of zovegalisib and other pipeline development.

8-KPress release / Reg FDMay 198-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

Relay Therapeutics, Inc. (RLAY) released initial Phase 2 ReInspire trial clinical data for zovegalisib in vascular anomalies via Reg FD press release (Exhibit 99.1) and a slide presentation (Exhibit 99.2) on May 19, 2026, with a live conference call and webcast at 8:00 a.m. ET. This represents a pivotal Phase 2 data readout for zovegalisib in a rare vascular indication, with efficacy and safety results that could define the drug's further development path and materially impact the company's pipeline value.

8-KPress release / Reg FDApr 278-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

RLAY filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-04-27. Covers: slide presentation to accompany the call, a copy of which is being furnished as Exhibit 99. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

+ 22 other (10 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimateszacks.com·9d agoRelay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updatesglobenewswire.com·9d agoRelay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026globenewswire.com·16d agoRelay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?zacks.com·16d agoAn AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbersprnewswire.com·23d ago

In themes

Explore the broader themes this ticker is being talked about under.

Best PerformersAI Precision Medicine

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ABCL$CAPR$ALLO$NWBO$TENX$AURA$SION$IBRX
Voices on X · top 4 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport